Caribou Biosciences (NASDAQ:CRBU) Stock Bumped Down to Hold by Brookline Capital Markets

Caribou Biosciences (NASDAQ:CRBU) was downgraded by investment analysts at Brookline Capital Markets from a “buy” rating to a “hold” rating in a report released on Wednesday, Marketbeat.com reports.

A number of other research analysts have also recently issued reports on CRBU. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. Bank of America cut their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Royal Bank Of Canada lowered shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price for the company. in a report on Wednesday. Leerink Partners reissued a “market perform” rating and issued a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a research report on Wednesday. Finally, Wall Street Zen cut Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.50.

Caribou Biosciences Price Performance

CRBU stock opened at $0.62 on Wednesday. Caribou Biosciences has a 1 year low of $0.55 and a 1 year high of $3.54. The firm has a 50-day moving average of $1.45 and a 200 day moving average of $1.75. The company has a market cap of $66.19 million, a P/E ratio of -0.57 and a beta of 2.31.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. The company had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. On average, equities research analysts expect that Caribou Biosciences will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $13,756,000. Renaissance Technologies LLC raised its stake in Caribou Biosciences by 58.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock valued at $4,922,000 after buying an additional 950,640 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Caribou Biosciences during the 2nd quarter valued at $2,483,000. GSA Capital Partners LLP purchased a new position in shares of Caribou Biosciences in the 2nd quarter worth $816,000. Finally, Green Alpha Advisors LLC purchased a new stake in Caribou Biosciences during the second quarter valued at $641,000. 77.51% of the stock is currently owned by institutional investors.

Trending Headlines about Caribou Biosciences

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Caribou is evaluating strategic alternatives intended to maximize stockholder value. A sale, merger or other transaction could potentially provide value beyond the company’s standalone prospects, although there is no assurance that a transaction will occur. Caribou Biosciences to Evaluate Strategic Alternatives
• Neutral Sentiment: Leerink Partners downgraded CRBU from “outperform” to “market perform” but assigned a $1.00 price target, which remains above the stock’s recent $0.62 reference price. Brookline Capital Markets also maintained a “hold” rating. Leerink Partners Downgrades Caribou Biosciences
• Negative Sentiment: The company plans to halt two key CAR-T programs and cut its workforce, materially reducing its clinical pipeline and future growth prospects. The decision followed challenges in advancing its off-the-shelf cell-therapy strategy and was the primary catalyst for the recent selloff. Caribou Biosciences To Halt Two CAR-T Programs
• Negative Sentiment: RBC downgraded Caribou from “outperform” to “sector perform” and slashed its price target from $10 to $1 while retaining a speculative-risk designation. The downgrade reflects reduced confidence in the company’s development pipeline and heightened uncertainty surrounding the strategic review. RBC Downgrades Caribou Biosciences
• Negative Sentiment: Investor reaction has been sharply negative, with reports describing a roughly 40% or greater plunge in the shares following the program cancellations. CRBU remains an unprofitable biotechnology company, increasing its dependence on a successful strategic transaction or future pipeline restart. Caribou Shares Fall After Plans to Evaluate Strategic Alternatives

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.